News
A 30% reduction of adverse drug reactions with a pharmacogenomic test.
This EU multicenter cross-over study was designed to have 80% power to detect a 30% difference in incidence of clinically relevant Adverse Drug Reactions (ADR) within 12-week follow-up period. The study was able to show a significant 30% reduction of the risk of ADR in the patient group using [...]
New antidepressants study from Norway
The most favourable genotype for SSRI metabolism includes CYP2D6, CYP2C19 and SLC6A - but the findings show a low prevalence. https://tidsskriftet.no/en/2022/09/original-article/genotyping-patients-treated-selective-serotonin-reuptake-inhibitors
Hvad kan pharmacogenomics hjælpe dig med?
En kort of fin forklaring på hvad pharmacogenomics kan hjælpe dig med. Denne video er fra Florida og derfor ikke en lokal reklame. http://https://www.youtube.com/watch?v=b9FyOAEXzBw&t=12s
The use of PGx in Nursing Homes
Four Nursing Homes in Ontario. Measurements Potential drug therapy problems (DTPs) for study cohort were identified during a medication review by a pharmacist using pharmacogenetic (PGx) clinical decision support to identify medication change opportunities. The number of DTPs identified during a standard medication review was compared with the number [...]
Approaches and hurdles of implementing PGx in psychiatric clinic
Despite the many hurdles, PGx testing has great promise to optimize medication selection and dosing in psychiatry practice. While the clinical evidence‐base is growing, a collaborative multi‐stakeholderapproach can overcome hurdles discussed in this review. The development of user‐friendly systems for test ordering, guidelines for use and communication of results, [...]
Time course for benefits and risk with dual antiplatelet therapy
Question What is the time course for benefit and risk with dual antiplatelet therapy for individuals with minor ischemic stroke or transient ischemic attack (TIA) who carry CYP2C19 loss-of-function (LOF) alleles? Findings In this secondary analysis of the Ticagrelor or Clopidogrel With Aspirin in High-risk Patients With Acute Nondisabling Cerebrovascular Events II (CHANCE-2) [...]